Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bacterial Meningitis II: Pathophysiology01:26

Bacterial Meningitis II: Pathophysiology

Bacterial meningitis typically begins when pathogens such as Neisseria meningitidis and Streptococcus pneumoniae colonize the nasopharynx and invade the bloodstream. This process is facilitated by bacterial virulence factors, such as polysaccharide capsules, which resist phagocytosis and complement-mediated killing. Less commonly, bacteria reach the central nervous system via contiguous spread from infections like otitis media or sinusitis, through congenital or acquired dural defects, or...
Bacterial Meningitis01:24

Bacterial Meningitis

Bacterial meningitis is a severe infectious disease involving inflammation of the meninges, the protective membranes surrounding the brain and spinal cord. It occurs when pathogenic bacteria cross the blood–brain barrier and enter the cerebrospinal fluid. Common causative organisms include Neisseria meningitidis, Streptococcus pneumoniae, Haemophilus influenzae type b, Listeria monocytogenes, and Escherichia coli K1. The exact route of entry varies by pathogen and host condition.Routes of Entry...
Bacterial Meningitis I: Introduction01:22

Bacterial Meningitis I: Introduction

Bacterial meningitis is a severe, life-threatening inflammation of the meninges, particularly the pia mater and arachnoid mater, affecting the subarachnoid space, ventricles, and cerebrospinal fluid (CSF). If untreated, it can lead to significant neurological complications or death.Causative AgentsCommon pathogens vary with age and immune status. In adults, major organisms include Streptococcus pneumoniae, Neisseria meningitidis, and Haemophilus influenzae. Streptococcus agalactiae (group B...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical outcomes of toxin-positive versus toxin-negative/NAAT-positive Clostridioides difficile infection in South Korea: a single-center retrospective cohort study.

BMC infectious diseases·2026
Same author

Comparison of hybrid-and mono-pathotype Escherichia coli isolates from South Korea based on whole genome analysis and cytotoxicity assay.

Journal of biomedical science·2026
Same author

Long-term clonal dynamics of sequence type 72 among methicillin-resistant and methicillin-susceptible Staphylococcus aureus in Korea.

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases·2026
Same author

In vitro activity of double and triple antimicrobial combinations against carbapenem-resistant Pseudomonas aeruginosa biofilm.

The Journal of antimicrobial chemotherapy·2026
Same author

Changes in Sero-Immunological Status for Infectious Diseases in Solid Organ Transplantation: A 20-year Single-Center Study in Korea.

Annals of laboratory medicine·2026
Same author

Transition from Cytomegalovirus Antigenemia Assay and Whole-Blood Quantitative PCR to Automated Plasma Quantitative PCR in Solid Organ Transplant Recipients: Correlation of Viral Loads and Impact on Treatment Eligibility Based on a Single-Center Retrospective Study.

Annals of laboratory medicine·2025

Related Experiment Video

Updated: Jun 23, 2026

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
09:17

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

Published on: January 2, 2017

Daptomycin in experimental murine pneumococcal meningitis.

Barry B Mook-Kanamori1, Mark S Rouse, Cheol-In Kang

  • 1Division of Infectious Disease, Department of Internal Medicine, College of Medicine, Mayo Clinic, Rochester, MN, USA. mook.barry@mayo.edu

BMC Infectious Diseases
|May 2, 2009
PubMed
Summary

Daptomycin and vancomycin, with dexamethasone, effectively treat experimental pneumococcal meningitis in mice. Both antibiotics showed similar efficacy in reducing bacterial meningitis.

More Related Videos

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

Inducing Meningococcal Meningitis Serogroup C in Mice via Intracisternal Delivery
10:03

Inducing Meningococcal Meningitis Serogroup C in Mice via Intracisternal Delivery

Published on: November 5, 2019

Related Experiment Videos

Last Updated: Jun 23, 2026

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
09:17

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

Published on: January 2, 2017

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

Inducing Meningococcal Meningitis Serogroup C in Mice via Intracisternal Delivery
10:03

Inducing Meningococcal Meningitis Serogroup C in Mice via Intracisternal Delivery

Published on: November 5, 2019

Area of Science:

  • Infectious Diseases
  • Pharmacology
  • Neuroscience

Background:

  • Pneumococcal meningitis poses a significant health challenge.
  • Vancomycin is a standard treatment, but alternatives are sought.
  • Daptomycin shows potential as an alternative antibiotic for meningitis.

Purpose of the Study:

  • To evaluate daptomycin's efficacy against vancomycin in a murine model of pneumococcal meningitis.
  • To assess the role of dexamethasone as an adjuvant therapy.
  • To compare the impact of these treatments on bacterial load and brain pathology.

Main Methods:

  • A murine model of Streptococcus pneumoniae meningitis was established using bioluminescent bacteria.
  • Mice were treated with dexamethasone alone, or in combination with vancomycin or daptomycin.
  • Cerebrospinal fluid (CSF) bacterial concentrations, bioluminescence, and brain apoptosis were measured.

Main Results:

  • Both vancomycin and daptomycin significantly reduced CSF bacterial titers compared to untreated controls.
  • No significant difference in bactericidal activity was observed between vancomycin and daptomycin.
  • CSF bioluminescence correlated with bacterial load, and apoptosis levels were similar across treatment groups.

Conclusions:

  • Daptomycin and vancomycin, when combined with dexamethasone, demonstrate activity against experimental pneumococcal meningitis.
  • These findings support daptomycin as a potential therapeutic option for pneumococcal meningitis.